-
Yunnan white medicine and other products to raise prices OTC ushered in a sustained wave of price increases?
Time of Update: 2021-02-28
an interview with Securities Daily, a Chinese pharmaceutical executive said that since the state liberalized the market pricing power of OTC drugs, the company's low-cost product prices gradually increased.
-
The prospects for the restructuring of Tonghua Jinma, which is proposed to purchase the risk target of 2.19 billion yuan, are highly predictable
Time of Update: 2021-02-28
In 2016, 2017 and January-March 2018, Hekang Cancer Hospital's sales to Crane Mining Group and its related parties accounted for 77.96 percent, 68.55 percent and 59.76 percent of operating income, respectively.
-
The latest official response from Huahai Pharmaceuticals has come after the recall
Time of Update: 2021-02-28
Huahai Pharmaceuticals immediately issued a notice explaining that the company in the process of optimizing the production process of the raw materials of nitrate tan, under the unknown impurities, found and detected one of the unknown impurities is nitrodi methamphetamine (NDMA).
-
Kangmei took another county distribution of a number of pharmaceutical companies to buy sanjia hospital
Time of Update: 2021-02-28
Kangmei buy hospital has a new action, take a county distribution. In 2018, these triple-A hospitals have been bought by pharmaceutical companies. yesterday (August 6), Kang Meifa announced that it w
-
Trade war China has hit back at tariffs on medical devices imposed on the United States and Canada
Time of Update: 2021-02-28
December 2015, three catalogues were revised again, and for the first time three medical equipment products were included in the catalogue of major technical equipment and products supported by the State, thus enjoying the duty-free benefits of importing some key components and raw materials from domestic enterprises.
-
In the first half of the year, the fund's top 30 stocks were 90% heavy-stock pharmaceutical stocks
Time of Update: 2021-02-28
The performance of the two fund managers was eye-catching in the first half of this year, the market as a whole fell, with only leisure services, pharmaceuticals, biology and food and beverage rising among the 28 first-tier sectors, while 20 sectors fell by more than 15%, with 11 industry indices such as communications, electrical equipment, machinery and equipment, non-ferrous metals, construction decoration and electronics falling by more than 20%.
-
Connbey: Revenue of RMB3,577 million Net profit up 42.62%
Time of Update: 2021-02-28
According to statistics, the series of brand products included in its large-brand large-variety engineering projects achieved a cumulative sales revenue of 2.629 billion yuan, an increase of 69.67 percent over the same period last year.
-
The company's 2018 acquisition plans continue to be expected to take in 10 drugmakers
Time of Update: 2021-02-28
The company's 2018 acquisition plans are ongoing, with more than 10 nationally distributed pharmaceutical commercial or terminal retail businesses expected to cover at least 150,000 end-stores, community health care and clinics during the year.
-
Hengrui's market capitalization broke 300 billion pharmaceutical companies ranked reshuffle
Time of Update: 2021-02-28
Hengrui Pharmaceuticals has invested 98 million yuan in the research and development project of sulfur-pei non-Gestin injection, which is expected to drive the company's performance growth after listing.
-
Drug Mingkangde 13 board market value of more than 100 billion
Time of Update: 2021-02-28
Drug Mingkangde 24 again rose and stopped, the stock has been 13 consecutive days of ups and downs (including the first day of 44% rise), as of the release, the stock did not open the rise and stop, a
-
China Resources Shuanghe acquired Xiangzhong Pharmaceuticals to take an 80% share of the region
Time of Update: 2021-02-28
June 4, China Resources Shuanghe announced that it will use its own funds to acquire a 40% stake in China Resources Shuanghe Limin Pharmaceuticals (Jinan) Co., Ltd. for 847.66 million yuan.
-
Raith Medical expects a first-half loss of $55 million to $85 million
Time of Update: 2021-02-28
On the evening of August 6th, Ruixi Medical (01526, HK), one of the giants of the private medical examination industry, announced its results forecast for the first half of 2018, with net losses of between RMB55 million and RMB85 million (the same as under units), a significant increase over the same period last year.
-
Shanghai Pharmaceutical Eye Capital operates frequently Investors question the performance of share prices
Time of Update: 2021-02-28
Shanghai Pharma's 2017 Annual Report shows that in order to maintain the profitability of its distribution business, the company continues to optimize its product structure, promote Lean Six Sigma management to strengthen cost control, and further expand the hospital supply chain innovation services, a total of 226 hospital pharmacies, 97 new.
-
Tengsheng Bo Pharmaceuticals was established and received $260 million in financing from six well-known institutions
Time of Update: 2021-02-28
announced the financing, TengshengBo Pharmaceuticals announced that it has reached an important strategic partnership with a number of enterprises to accelerate the development of infectious disease drugs in China, through advanced technology and data to help the development of China's public health system, thereby benefiting the vast number of patients.
-
Four-price HPV half-year sales of 2.62 million Zhifei biological net profit increased 297%
Time of Update: 2021-02-28
Up to now, four-price HPV has been in the country's 29 provincial units winning the bid, promotion, sales work is also under way.
-
Liao let go of the Chinese medicine formula particles in the national blank area is not much left
Time of Update: 2021-02-28
On June 19th, Liaoning Provincial Health and Planning Commission, Industry and Information Technology Commission and Food and Drug Administration jointly issued the Notice on the Declaration of Special Projects for Research on Chinese Medicine Formula Particles in Liaoning Province (hereinafter referred to as Notification).
-
Shandong expands the scale of targeted training of public-funded orders for rural medical students
Time of Update: 2021-02-28
Lixin, deputy director of the Shandong Provincial Health and Family Planning Commission, said that Shandong has implemented a public-funded training program for targeted medical students for rural orders, with 1,000 undergraduate students enrolled each year for five-year courses.
-
Tiansli Pre-IPO round has the highest valuation, being the largest unicorn in the domestic biopharmaceon field
Time of Update: 2021-02-28
("Tiansli Bio"), an innovative biopharmaceutical company with a listed heavy-weight product in the cardiovascular sector and the industry's ability to develop pipelines, announced the completion of the Pre-IPO round of financing, with a post-investment valuation of 12.5 billion yuan ($1.9 billion).
-
The total industrial output value of Yunnan biopharmaceutical industry is 46.5 billion yuan
Time of Update: 2021-02-28
Yunnan Provincial Committee, provincial government, Kunming Municipal Committee, the municipal government issued a series of incentives, support preferential policies, expanding the size of the pharmaceutical and medical services market, for the transformation of resources, industrial upgrading, rapid development of trade and commerce provides a good opportunity, so that the development prospects of the biopharmaceutical industry is more and more broad.
-
Four billion! Yuheng Pharmaceuticals to buy turnover of 1.44 million yuan company
Time of Update: 2021-02-28
On July 10, Yu heng Pharmaceuticals issued a public announcement on the progress of its major asset restructuring, which showed that Yuheng expects to acquire no less than 35% of Tymco Bio for no less than 4 billion yuan in order to gain control of Tyme Bio. The final price is based on audit and evaluation and shall be determined by the two parties in consultation separately.
